Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Asthma
- Vol. 58 (1), 79-84
- https://doi.org/10.1080/02770903.2019.1658208
Abstract
Background: The interleukin 5 (IL-5) pathway is an important component in the pathophysiology of severe eosinophilic asthma. Mepolizumab is a monoclonal antibody that targets the IL-5 pathway. Clinical trials showed efficacy of Mepolizumab in patients with severe eosinophilic asthma. However, reports on experience with treatment in a real-world cohort are limited. Objectives: Evaluation of the efficacy and safety of Mepolizumab for treatment of severe eosinophilic asthma in a real-world cohort of patients. Methods: A clinical prospective observational trial included all patients >18 years treated with Mepolizumab between March 2016 to March 2019 at Rabin Medical Center. The composite primary outcome measures evaluated: increase in FEV1 by >= 200 ml and/or decrease in exacerbation rate of >= 50% and/or cessation of oral corticosteroids (OCS) treatment or >= 50% decrease in dosage. Also evaluated: blood eosinophil count, adverse events and quality of life. Results: Of 61 patients, 50 (82.0%) achieved the primary outcome. The number of patients who suffered from frequent exacerbations decreased from 52 (85.2%) to 8 (13.1%) (p < 0.001). Twenty-two patients (68%) stopped OCS treatment or received >50% reduced dosage (p < 0.001). Mean FEV1 increased from 1.72 +/- 0.78 liters to 1.87 +/- 0.85 liters (p = 0.043). Response to therapy was seen within six months. Forty-nine patients (80%) reported an improvement in quality of life (p < 0.001). Only minor adverse events were reported. Conclusion: Treatment with mepolizumab was well tolerated and significantly lowered the exacerbation rate and OCS dependence in a real-world cohort of severe eosinophilic asthma patients. Response to therapy was within six months and treatment effect was sustained over time.This publication has 24 references indexed in Scilit:
- Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumabDrug Design, Development and Therapy, 2017
- Anti-interleukin 5 therapies in severe asthmaThe Lancet Respiratory Medicine, 2017
- Targeting the interleukin pathway in the treatment of asthmaThe Lancet, 2015
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaThe New England Journal of Medicine, 2009
- Mepolizumab for Prednisone-Dependent Asthma with Sputum EosinophiliaThe New England Journal of Medicine, 2009
- Sputum CD34+IL-5Rα+ Cells Increase after AllergenAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Allergen-induced Increases in Bone Marrow T Lymphocytes and Interleukin-5 Expression in Subjects with AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells.The Journal of Experimental Medicine, 1986